Testosterone in cardiometabolic and other diseases
- ISBN/EAN
- 9788855321136
- Editore
- Minerva Medica
- Formato
- Libro in brossura
- Anno
- 2022
- Pagine
- 274
Disponibile
This book is very timely as several recent studies have demonstrated the important role of testosterone in the development of type 2 diabetes and metabolic syndrome. Testosterone is a highly controversial but vitally important hormone in men’s health. The traditional approach has been to classify low testosterone, or hypogonadism as either primary, due to disorders of the testes and therefore “classical” and meriting testosterone therapy, or secondary, where treatment may be indicated when due to structural pituitary or hypothalamic disorders. These include so-called functional causes, such as obesity, diabetes and medications where management through lifestyle change might be considered appropriate. The problem with this approach is that lifestyle changes are often either ineffective or of short-term benefit. These functional cases suffer just as readily in terms of new onset diabetes, sexual dysfunction, depression, cognitive disorders and most importantly increased mortality. The authors discuss in detail the role of testosterone and other therapeutic approaches to these problems as demonstrated by recent studies, such as T4DM, the T trials and BLAST, along with the possible impact of the long-awaited TRAVERSE study. The recent Covid-19 pandemic has caused increased mortality in men associated with profound and acute falls in testosterone that are closely linked with adverse outcomes across multiple medical disciplines. The reality is that Covid-19 is now probably the major cause of hypogonadism, with acute and long-term implications. The authors have assembled a team of international experts in andrology to address highly controversial issues in the chapters that follow
Maggiori Informazioni
| Autore | Hackett Geoffrey I.; Kirby Michael |
|---|---|
| Editore | Minerva Medica |
| Anno | 2022 |
| Tipologia | Libro |
| Lingua | Inglese |
| Indice | Introduction: the politics of testosterone David R. Edwards Diagnosis and terminology in hypogonadism Patricia E.S. Schartau Issues regarding testosterone measurement and use of reference ranges in men Mark Livingston, Rachel Marrington Adult-onset testosterone deficiency: changes in SHBG and the role of calculated free testosterone Richard C. Strange, Nathan Lorde, Amro Maarouf, Geoffrey I. Hackett, Sudarshan Ramachandran Adult-onset testosterone deficiency, incident diabetes and mortality Amro Maarouf, Nathan Lorde, Sudarshan Ramachandran Testosterone, obesity and metabolic dysfunction Thomas M. Barber, Hanson Petra, Martin O. Weickert Testosterone and anaemia Tharu Tharakan, Suks Minhas, Channa N. Jayasena Association between haematocrit and health outcomes Richard C. Strange, Nathan Lorde, Amro Maarouf, Geoffrey I. Hackett, Sudarshan Ramachandran Testosterone therapy in diabetes Geoffrey I. Hackett Management of hypogonadism in diabetes Geoffrey I. Hackett Guidelines of testosterone in type 2 diabetes Geoffrey I. Hackett Cardiovascular benefits and risks of testosterone therapy Geoffrey I. Hackett The role of PDE5 inhibitors in hypogonadism and diabetes Geoffrey I. Hackett Hypogonadism and fertility: alternative therapies Rowland W. Rees Testosterone and the prostate Rowland W. Rees Testosterone, frailty, mood and quality of life Adrian Heald Osteoporosis and serum testosterone levels: the impact of testosterone therapy Michael Kirby, Geoffrey I. Hackett Testosterone, diabetes and COVID-19 Michael Kirby Future developments in hypogonadism and diabetes and the role of androgen receptor sensitivity T. Hugh Jones Opioids, testosterone and men’s health Janine David, Michael Kirby Testosterone case studies Janine David |
| Larghezza | 0 |
| Stato editoriale | In Commercio |